5114/2020, CT ions cau —_|co key Sator sis Member's Login Home Equitymaster Home Fundamental ‘StockSolect Permanent Wealth Circle Phase One Alert Smart Money Secrets ValuePro Microcap Millionaires Double Income Exponential Profits Power Profits Profit Velocity Equitymaster Insider Wealth Alliance Reserve 'Pos Features Private Briefing Investor Hour Wading Breakout Profits Weekly Cash Alert Fast Profits Report Fast income Alerts beaming DeriVantage Equitymaster’s Secrats ‘erping You Build Wealth With Honest Research ‘Since 1996, Try Now | so wytes htps:ww: equitymaster comiresearch.isector-infolpharma/Pharmaceuticals-Sector-Analysis- Report asp Indian Pharmaceuticals Indusity Report -Pharmaceuticals Sector Research & Analysis nea - Equiymaster 18Indian Pharmaceuticals Indusity Report - Pharmaceuticals Sector Research & Analysis nea - Equitymaster Learning Forum ‘About Feam Today's Market Today's Market Read Today's Commentary BSE Replica AIIBSE Indices ADRs Key Sector Quotes NSE Replica AIINSE Indices Fits Market Stats Other indices International Market indices Gora ack Your Stocks My Stocks Portfolio Tracker Premium Premium Servi Fundamental StockSelect Hidden Treasure Permanent Wealth Circle Phase One Alert Smart Money Secrets ValuePro Microcap Millionaires Double Income Exponent Profits Power Profits Profit Velocity Equitymaster Insider hips wo equitymastercomiresearchsector-infolpharmayPharmaceuticals-Sector-Analysis Report. asp472020 Indian Pharmaceuticals Indusity Report - Pharmaceuticals Sector Research & Analysis nea - Equitymaster Wealth Alliance Reserve 'Pos Features Private Briefing Investor Hour Wading Breakout Profits Weekly Cash Alert Fast Profits Report Fast income Alerts ua ing Derivantage TradeMaster Equitymaster’s Secrets OptionMaster Learning Forum Research it Gompany Info Factsheets Compare Company Company Results Sector ito Sector Reports Sector-wise Results Outlook Start Hore! Recommended Reading Timeless Reading Free Newsletters ‘The 5 Minute Wrapup Profit Hunter Fast Profits Daily ‘The Honest Truth hips wo equitymastercomiresearchsector-infolpharmayPharmaceuticals-Sector-Analysis Report. aspsia2020 Ingian Pharmaceuticals Industy Report - Pharmaceuticals Sector Research & Analysis in Inda-Equtymastor Vivek Kaut's Diary Views on News Read Here ‘The Outside View Rortfolio Portfolio Tracker Rortfotio Register Demo Portfolio Tutorials Release Notes Terms Of Use Mobile Mobile App ‘Feust Equitymaster Twust Equitymastor Why Trust Equitymaster? Testimonials Hidden Treasure ValuePro Microcap Millionaires Portfolio Tracker Dervantage ‘Tradomaster Equitymaster's Secrets Help Sitemap How To Reach Us Advertising Info Legal hips wo equitymastercomiresearchsector-infolpharmayPharmaceuticals-Sector-Analysis Report. aspsyar2020 Ingian Pharmaceuticals Industy Report -Pharmaceuticals Sector Research & Analysis in naa -Equitymaster Press Release About ‘The Equitymaster W Rrofit Hunter Muitibagger Stock Weas How to Profit from Sensex 100,000, How to Beat Sensex Nea 15 Mistakes to Avoid while Investing in Stock Markets ‘The 2020 Small Cap Gulde oe quote Go Key Sector Stocks Go oe Rese Feri Pama ony 22.200 Pharmaceuticals Sector Analysis Report + How! {he Ponts racial Yat 19 Prospect |Setr Dos a ots Urgent Release: The COVID-10 Rebound Guide. DOWNLOAD NOW. India enjoys a key postion inthe global pharmaceutical incusty. The county le the workts largest supplier of generics, accounting for 20% of global exports, It supplies over 50% of global demand for various vaccines ‘and 40% of the demand for generic products in the US. The domestic pharmaceutical market contributes to 2% of the global industry in value and ~10% in volume terms, +The domestic pharmaceutical Industry has received foreign dec avstment (FDI) worth USS 16 bilion on a cumulative bass, between Api 2000 and June 2018 ‘ounrorsioeas +The industiy has played a key role in cvng beter health outcomes across the word through is affordable — and bighquaty generics drugs, Increases accessibily to affordable drags hasbeen one of the key enablers for lowering the disease burden in India. nd’ pe person disease burden measured as Dsabity Adjusted ees Life Yours (DALY) droppe by 26% using for changes nthe population age stucture. 2, Arevou mals 1. Howe Trade rSowniond During the year, crug penetration in India increased by 50%. India has now become Pollofree5, asa result of 5 guide too ‘tong collaboration among vaccine manufacturers, healthcare providers, the government and development erative st organisations. Download Fo: 4. Free Report: + The industry has also helped in bringing down the treatment coste of Mfetheeatening diseases such as Inereasing Yo Chronic Myeloid Leukemia and Hepatis Co less than St of the original cost. tt 5. No Guessing, + na enjoys an important poston in he global pharmaco sector. Te county als has a fage poo of Mid rane ‘cients and engineers wh have te potent ster he inst ahead oan even higher level Preset over 80% ofthe arte crugs used bball to combat AS (Acre immune Defcency Syme) sar scvearican are soppy Ian pharmaceutical fms ste OW To RESEARCH THE PHARMACEUTICAL SECTOR KEYPOINTS) var surely Higher for tadtonalteapeute segments, ths Ie pea ofa devlophg markt Relatively loner orfese segment — htps:ww: equitymaster comiresearch.isector-infolpharma/Pharmaceuticals-Sector-Analysis- Report asp se5114/2020, Indian Pharmaceuticals Indusity Report - Pharmaceuticals Sector Research & Analysis nea - Equitymaster Demand Very high for certain therapeutic segments. Will change as Ife expectancy, Iteracy riers to entry Distribution network, patents, developing and manufacturing capabilities, Bargaining power of Varies {rom market to market For instance, conelidation in US has led to pricing wa in supplier ‘generics, In India, distributors are increasingly pushing branded products in a bid to earn bigher margins, Bargaining power of High, a fragmented industry has ensured that there is widespread competion in almost buyers all product segments. Currently, the domestic markets also protected by the DPCO, Competition High and fragmented owing to many small players inthe industry. FINANCIAL YEAR"19 + The country’s pharmaceutical industry is expected to expand al a CAGR of 22.4% over 2015-20 to reach USS ‘5S illon. The pharmaceutical sector was valued at USS 33 bill in the previous year. Indl pharmaceutical exports stood at US$ 17.27 billon In FYTB and reached USS 19.1 billon In FYT9. Pharmacestical exports include bulk crugs, intermediates, drug formulations, biologicals, Ayush & herval products and surgicale 1+ The exports of Indian pharmaceutical industry to the US will get a boost, as branded drugs worth USS 55: billon wil become off-patent during 2018-2019, For the US market, Indian companies are developing niche Portfolios in various segments. High margin injectables, dermatology, respiratory, biosimilas, complex ‘generics ete, have become an ates of interest, Most ofthe Indian phatma companies have been working on these. Major companies have increased their RED spend to bulld pipeline of niche drugs. ‘The National Heath Protection Scheme is largest government funded healthcare programme in the world, which is expected to benefit 100 milion poor families inthe country by providing a cover of up to Re 5 lk (USS 7,723.2) per family per year for secondary and tertiary care hospitalization. The programme was ‘announced in Union udget 2018-79, +The Incian goverment has taken many steps to reduce costs and bring down healthcare expenses, Speedy Introduction of generic drugs into the market has remained in focus and is expected to benef the Indian Pharmaceutical companies, In addition, the thrust on rural health programmes, lifesaving dugs and preventive vaccines also augurs well forthe pharmaceutical companies. 1+ Exchange Rate Used: INR 1 = USS 0.0159 as on March 31,2019, PROSPECTS Pharmaceutical spending in developed markets is kel to grow at 25% CAGR between 2018-22 compared to {5.8% In the 2013-17 period. While launch of innovative products is likely to drive growth, is expected to be balanced by patent expres of existing products Innovation in new drug development, immunotherapy, next generation biotherapeutics, including celhbased gene therapies and digital health tools wll gin importance in the fture ofthe healthcare industy. India and Russia are expected to grow fasten comparison, averaging at 10% in the same time span, whe ‘the other phaima emerging markets wil average 6.9%. htps:ww: equitymaster comiresearch.isector-infolpharma/Pharmaceuticals-Sector-Analysis- Report asp compare company s0COM (oan ‘Congr th ead Sectors ‘Gis Tey oe5114/2020, Indian Pharmaceuticals Indusity Report - Pharmaceuticals Sector Research & Analysis nea - Equitymaster ++ Global population is projected to exceed 9.3 billon by 2060, of which 21% willbe accounted fr by those aged 60 and above. As individuals become increasingly health conscious and medical science continues to advance, fe expectancy will increase. By 2049, Japan, Singapore, Spain and Switzerland are projectee to have a life expectancy rate in excess of 85 years, while 59 counties, including China are expected to surpass a ife expectancy of 80 years during that period + Grovth in global pharmaceutical spening through 2023 will primarily be driven by developed markets and the accelerated adoption of new innovative products. Spending on medicines in developed markets is estimated to grow at 36% CAG from US$ 800 Billion in 2078 to US$ 980-1,020 Billon in 2023. +All developed countries wil show moderation in growth through 2023, as compared to the 2014-18 period ‘Specfeally nthe US, the positive impact of new specialty launches will be partly moderated by loss of patent protection on older products, Related Links for Pharmaceuticals Sector ‘uartery Results | Sector Quote |Over The Years Te eee cote Cog) In this report, we reveal four proven strategies to Peking mult Dagger stocks, ‘Well over a milion copies of this report nave alreagy been claimed aver the years Don't miss it for anything VIEWS ON NEWS: (MosT POPULAR. Sony Thee we no feted views on news for Cle Thisis When the Stock Market WillBottom Out compunyiaeton Fan Prote 300) ‘ase classes need aon st ht. ‘AStock that Will Beat the 40% Gains inthe Pharma Sector Hands Down Perera 1 ie i parma stocks hve shocked you wale ou frit The Time to Buy Gold Has Arrived (ras Profs D0h| wal you what te ‘The Next Sector to Outperforms Probably Not the ‘One Youre Bullsh on Now hye ndererfomanoe of ankig stocks eau ed son htps:ww: equitymaster com/research.isector-infolpharma/Pharmaceuiicals-Sector-Analysis Report asp5114/2020, Indian Pharmaceuticals Indusity Report - Pharmaceuticals Sector Research & Analysis nea - Equitymaster ‘The 36.2436 prtfoliowitha Séinch chest! ‘A Osalon how to wak around wth 2 5 ach chest i the sour equrwasten ‘Snoe 1986, Equitymaster as been the source for honest an crete opinions cn investing in li, With sli esenrch and ir-dgth anal Equtymaster ie dedicated towards mates mare concent ana rer everyday Here's why hundreds of thousands of ears spread-acroas more than 7 counties Trust Equtyaster reeneveterans prem pnooucts quiexunis ers rouow Prof se Equtymastor ier TrustEquynaser Fam Profs Only sen Tease Tre Egat Vay The Honest Th iro ons: Equtymaster FAQ xotertal Prot Views an ews Archive hate Ore le, Today Stack Mate pate Prot alony ‘Sect Reports Stocksebst Ia tok Soreeer Valusre Patt ack Wee Cath et ‘costa ppt Fat rote Reort Fast heare Ae Copy © tnatyatr Aor Retrch Prat ned tea ter Toms Prey Cote Au Steed nse rae Pent ae fn 0 get Chante hp Sa est ne Fo mb 40002 a enc cebus Fe 220280 Una oGeqamter zm eee wn amasom NUP EPICS stig yo oy ent ams wate Wl aa pupae par ya tye sab ama egg ‘ype oa autre pan fe wet sui eosin ina ature ese pcan eer egrets Ane laon geen gue 204 an No, RODS? htps:ww: equitymaster comiresearch.isector-infolpharma/Pharmaceuticals-Sector-Analysis- Report asp ae